Development of a selective competitive receptor binding assay for the determination of the affinity to NR2B containing NMDA receptors

Journal of Pharmaceutical and Biomedical Analysis

Volumn 53, Issue 3, 2010, Pages 603-608

  Schepmann, Dirk ^a   Frehland, Bastian ^a   Lehmkuhl, Kirstin ^a   Tewes, Bastian ^a   Wünsch, Bernhard ^a  

^a INST OF REPRO MED OF THE UNIV   (Germany)

Author keywords

Binding assay.; Ifenprodil; NMDA receptor; NR2B; Recombinant receptor

Indexed keywords

DEXAMETHASONE; IFENPRODIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING KINETICS; BINDING SITE; CELL SPECIFICITY; CONTROLLED STUDY; HOMOGENATE; HUMAN; L CELL; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SCINTILLATION; ULTRASOUND;

ANIMALS; BINDING, COMPETITIVE; CELLS, CULTURED; HUMANS; MICE; PIPERIDINES; RADIOLIGAND ASSAY; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 77954861309     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.04.014     Document Type: Article

References (41)

1. Kew J.N., Kemp J.A. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl) 2005, 179:4-29.
2. Wollmuth L.P., Sobolevsky A.I. Structure and gating of the glutamate receptor ion channel. Trends Neurosci. 2004, 27:321-328.
3. Dingledine R., Borges K., Bowie D., Traynelis S.F. The glutamate receptor ion channels. Pharmacol. Rev. 1999, 51:7-61.
4. McBain C.J., Mayer M.L. N-Methyl-d-aspartic acid receptor structure and function. Physiol. Rev. 1994, 74:723-760.
5. Choi D.W., Rothman S.M. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu. Rev. Neurosci. 1990, 3:171-182.
6. Danysz W., Parsons C.G. Neuroprotective potential of ionotropic glutamate receptor antagonists. Neurotox. Res. 2002, 4:119-126.
7. Brauner-Osborne H., Egebjerg J., Nielsen E.O., Madsen U., Krogsgaard-Larsen P. Ligands for glutamate receptors: design and therapeutic prospects. J. Med. Chem. 2000, 43:2609-2645.
8. Foster A.C., Gill R., Iversen L.L., Kemp J.A., Wong E.H., Woodruff G.N. Therapeutic potential of NMDA receptor antagonists as neuroprotective agents. Prog. Clin. Biol. Res. 1990, 36:301-529.
9. Furukawa H., Singh S.K., Mancusso R., Gouaux E. Subunit arrangement and function in NMDA receptors. Nature 2005, 438:185-192.
10. Laube B., Kuhse J., Betz H. Evidence for a tetrameric structure of recombinant NMDA receptors. J. Neurosci. 1998, 18:2954-2961.
11. Cull-Candy S., Brickley S., Farrant M. NMDA receptor subunits: diversity, development and disease. Curr. Opin. Neurobiol. 2001, 11:327-335.
12. Chazot P.L., Stephenson F.A. Molecular dissection of native mammalian forebrain NMDA receptors containing the NR1 C2 exon: direct demonstration of NMDA receptors comprising NR1, NR2A, and NR2B subunits within the same complex. J. Neurochem. 1997, 69:2138-2144.
13. Cull-Candy S.G., Brickley S.G., Misra C., Feldmeyer D., Momiyama A., Farrant M. NMDA receptor diversity in the cerebellum: identification of subunits contributing to functional receptors. Neuropharmacology 1998, 37:1369-1380.
14. Dunah A.W., Standaert D.G. Subcellular segregation of distinct heteromeric NMDA glutamate receptors in the striatum. J. Neurochem. 2003, 85:935-943.
15. Chazot P.L. The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologies. Curr. Med. Chem. 2004, 11:389-396.
16. Chenard B.L., Menniti F.S. Antagonists selective for NMDA receptors containing the NR2B subunit. Curr. Pharm. Des. 1999, 5:381-404.
17. Gogas K.R. Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr. Opin. Pharmacol. 2006, 6:68-74.
18. Nikam S.S., Meltzer L.T. NR2B selective NMDA receptor antagonists. Curr. Pharm. Des. 2002, 8:845-855.
19. Mercer L.D., Jarrott B., Beart P.M. 125I-ifenprodil: synthesis and characterization of binding to a polyamine-sensitive site in cerebral cortical membranes. J. Neurochem. 1993, 6:120-126.
20. 3H]ifenprodil binding in rat brain. Eur. J. Pharmacol. 1994, 266:67-77.
21. 3H]ifenprodil binding to NMDA receptors in porcine hippocampal brain membranes. Eur. J. Pharmacol. 2000, 394:211-219.
22. 3H]Ro 25-6981, a potent and selective antagonist of NMDA receptors containing NR2B subunits. J. Neurochem. 1998, 70:2147-2155.
23. 3H]ifenprodil binding to sigma receptors in rat brain. Eur. J. Pharmacol. 1993, 236:159-163.
24. 3H](+)-3-PPP-labeled sigma binding sites in guinea pig brain membranes. Eur. J. Pharmacol. 1990, 176:247-248.
25. 3H](+)-3-PPP to sigma binding sites in rat brain. Neurosci. Lett. 1990, 116:190-193.
26. Grimwood S., Richards P., Murray F., Harrison N., Wingrove P.B., Hutson P.H. Characterisation of N-methyl-d-aspartate receptor-specific [(3)H]Ifenprodil binding to recombinant human NR1a/NR2B receptors compared with native receptors in rodent brain membranes. J. Neurochem. 2000, 75:2455-2463.
27. Steinmetz R.D., Fava E., Nicotera P., Steinhilber D. A simple cell line based in vitro test system for N-methyl-d-aspartate (NMDA) receptor ligands. J. Neurosci. Methods 2002, 113:99-110.
28. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
29. Stoscheck C.M. Increased uniformity in the response of the coomassie blue G protein assay to different proteins. Anal. Biochem. 1990, 184:111-116.
30. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22:3099-3108.
31. Ferkany J.W. The radioreceptor assay: a simple, sensitive and rapid analytical procedure. Life Sci. 1987, 41:881-884.
32. Motulsky H. Analyzing Data with GraphPad Prism 1995, Graph Pad Prism Software.
33. Bruns R.F., Lawson-Wendling K., Pugsley T. A rapid filtration assay for soluble receptors using polyethylenimine-treated filters. Anal. Biochem. 1983, 132:74-81.
34. 3H](+)-pentazocine to sigma recognition sites in guinea pig brain. Eur. J. Pharmacol. 1992, 227:371-378.
35. Geiger C., Zelenka C., Weigl M., Fröhlich R., Wibbeling B., Lehmkuhl K., Schepmann D., Grünert R., Bednarski P.J., Wünsch B. Synthesis of bicyclic sigma receptor ligands with cytotoxic activity. J. Med. Chem. 2007, 50:6144-6153.
36. Greengrass P., Bremner R. Binding characteristics of 3H-prazosin to rat brain alpha-adrenergic receptors. Eur. J. Pharmacol. 1979, 55:323-326.
37. Holl R., Schepmann D., Bednarski P.J., Grünert R., Wünsch B. Relationships between the structure of 6-substituted 6,8-diazabicyclo[3.2.2]nonan-2-ones and their sigma receptor affinity and cytotoxic activity. Bioorg. Med. Chem. 2009, 17:1445-1455.
38. Skuza G. Effect of sigma ligands on the cocaine-induced convulsions in mice. Pol. J. Pharmacol. 1999, 51:477-483.
39. Oberdorf C., Schepmann D., Vela J.M., Diaz J.L., Holenz J., Wünsch B. Thiophene bioisosteres of spirocyclic sigma receptor ligands. 1. N-substituted spiro[piperidine-4,4'-thieno[3,2-c]pyrans]. J. Med. Chem. 2008, 51:6531-6537.
40. Borza I., Domany G. NR2B selective NMDA antagonists: the evolution of the ifenprodil-type pharmacophore. Curr. Top. Med. Chem. 2006, 6:687-695.
41. Pabel J., Hofner G., Wanner K.T. Synthesis and resolution of racemic eliprodil and evaluation of the enantiomers of eliprodil as NMDA receptor antagonists. Bioorg. Med. Chem. Lett. 2000, 10:1377-1380.